Olopatadine/mometasone
Combination drug / From Wikipedia, the free encyclopedia
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][2][3] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][2] It is sprayed into the nose.[1][2]
Quick Facts Combination of, Mometasone ...
Combination of | |
---|---|
Olopatadine | Selective histamine H1-receptor antagonist |
Mometasone | Corticosteroid |
Clinical data | |
Trade names | Ryaltris |
Other names | GSP 301 |
License data | |
Pregnancy category |
|
Routes of administration | Nasal spray |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Close
Common side effects include an unpleasant taste (dysgeusia).[1]
It was approved for medical use in Australia in December 2019,[1][4] and in the United States in January 2022.[2]